GoodFellow

SGLT2 inhibitors and how we use them

Date Published
Duration
24.24
Category
Diabetes
Medication
Equity

In this podcast, Dr Rick Cutfield discusses the management of type two diabetes mellitus following the introduction of new funded medication in NZ.

He covers the importance of lifestyle, medication, and support at every step, and also the pharmacological management including the new stepwise approach to management.

Indications and precautions of the new classes of subsidised medications: Sodium glucose co-transporter 2 (SGLT-2) inhibitors, and briefly Glucagon like peptide-1 receptor (GLP-1) agonists are also covered.

Topics

  1. Play now
  2. Play now
  3. Play now
  4. Play now
  5. Play now
  6. Play now
  7. Play now
  8. Play now
  9. Play now

Take home messages

Resources

  1. Optimising pharmacological management of HbA1c levels in patients with type 2 diabetes: from metformin to insulin
  2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
  3. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
  4. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
  5. Proposal to fund two new medicines for type 2 diabetes
  6. Type 2 Diabetes Management Guidance

Presenter

Dr Rick Cutfield

Endocrinologist

Dr Rick Cutfield is the Clinical Director of the Endocrinology & Diabetes Division at Waitemata DHB. He is active in teaching, clinical research and all aspects of diabetes, endocrinology and general medicine.

You may also be interested in: